CSIMarket
 
Crinetics Pharmaceuticals Inc   (CRNX)
Other Ticker:  
 
 
Price: $43.0100 $-1.00 -2.272%
Day's High: $44.54 Week Perf: -3.54 %
Day's Low: $ 42.87 30 Day Perf: 10.48 %
Volume (M): 539 52 Wk High: $ 49.58
Volume (M$): $ 23,178 52 Wk Avg: $28.99
Open: $44.05 52 Wk Low: $15.76



 Market Capitalization (Millions $) 2,443
 Shares Outstanding (Millions) 57
 Employees -
 Revenues (TTM) (Millions $) 5
 Net Income (TTM) (Millions $) -199
 Cash Flow (TTM) (Millions $) -57
 Capital Exp. (TTM) (Millions $) 5

Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics for rare endocrine disorders and endocrine-related cancers. The company's research and development efforts aim to address significant unmet medical needs and improve the quality of life for patients. Crinetics' pipeline includes potential treatments for diseases such as acromegaly, neuroendocrine tumors, and congenital hyperinsulinism. By leveraging its expertise in peptide chemistry and small molecule drug design, Crinetics Pharmaceuticals strives to bring innovative therapies to patients worldwide.


   Company Address: 10222 Barnes Canyon Road San Diego 92121 CA
   Company Phone Number: 450-6464   Stock Exchange / Ticker: NASDAQ CRNX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Shares

Crinetics Pharmaceuticals Grants Stock Options to New Employees and Closes Oversubscribed $350 Million Private Placement

Published Thu, Apr 11 2024 8:05 PM UTC

Crinetics Pharmaceuticals Grants Stock Options to New Employees and Closes Oversubscribed $350 Million Private Placement
SAN DIEGO, April 11, 2024 - Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) made two significant announcements regarding its recent business activities. On April 10, 2024, the Compensation Committee of Crinetics Board of Directors granted non-qualified ...

Clinical Study

Acromegaly is a rare hormonal disorder caused by the excessive production of growth hormone (GH), which leads to the overgrowth of body tissues. Characterized by abnormal growth in certain body parts, such as the hands, feet, and face, acromegaly also results in various metabolic abnormalities and co-morbidities. One of the primary treatment s for acromegaly is to normalize the levels of insulin...

Published Tue, Mar 19 2024 10:00 AM UTC

Crinetics Pharmaceuticals, a clinical-stage biotechnology company focused on developing innovative therapeutics for rare endocrine diseases and endocrine-related tumors, has announced promising results from two separate studies evaluating the efficacy of their once-daily oral drug, paltusotine. In the Phase 3 PATHFNDR-2 study conducted in patients with acromegaly, paltusotin...

Clinical Study

Crinetics? Paltusotine Shows Positive Results in Phase 2 Trial for Carcinoid Syndrome Treatment

Published Tue, Mar 12 2024 8:05 PM UTC

Crinetics Announces Positive Results for Paltusotine in Phase 2 Trial for Carcinoid Syndrome Treatment - In a recent press release, Crinetics Pharmaceuticals reported positive topline results from its Phase 2 trial of paltusotine, a potential treatment for carcinoid syndrome. The trial demonstrated rapid and sustained reductions in the frequency and severity of flushing epis...

Shares

Crinetics Pharmaceuticals Thrives with Inducement Grants Amidst Investor Confidence and Growth Trajectory

Published Mon, Mar 11 2024 8:05 PM UTC

Crinetics Pharmaceuticals Continues Growth with March 2024 Inducement Grants Following Successful Public Offering in 2023
In recent news, Crinetics Pharmaceuticals, a leading biotechnology company focused on developing novel therapeutics for rare endocrine diseases, announced the granting of non-qualified stock option awards to new non-executive employees. These induceme...

Shares

Crinetics Pharmaceuticals Raises $350 Million in Oversubscribed Private Placement to Propel Rare Disease Therapeutics Development

Published Wed, Feb 28 2024 1:00 PM UTC

Crinetics Pharmaceuticals Raises $350 Million in Oversubscribed Private Placement
San Diego-based clinical-stage pharmaceutical company, Crinetics Pharmaceuticals, announced today that it has successfully completed an oversubscribed private placement, raising approximately $350 million in gross proceeds. The placement involved the sale of 8,333,334 shares of its common s...






 

Crinetics Pharmaceuticals Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com